Novartis has unveiled new clinical data for its renin inhibitor Rasilez--a potential blockbuster. The data demonstrates that Rasilez is better at reducing systolic blood pressure than standard treatment with an ACE inhibitor among patients with diabetes and hypertension. The data also demonstrates a sustained drop in blood pressure over 24 hours, a key signal among diabetes patients whose blood pressure often surges in the morning. Rasilez is being co-developed with Switzerland's Speedel, a 2005 Fierce 15 company. The data was presented at the Madrid meeting of the European Society of Hypertension.
- here's the AFX report on the data